NASDAQ: AVXL

NASDAQ: AVXL

Advancing Therapies for Complex Diseases

We are committed to addressing some of the most challenging and impactful conditions affecting individuals and their families.

Innovative Solutions, Meaningful Impact

From neurodegenerative diseases to rare genetic disorders, our approach is driven by cutting-edge science, a deep understanding of the complexities of these diseases, and a relentless dedication to improving lives.

Through our innovative therapies, we aim to restore hope, preserve quality of life, and transform the standard of care for these conditions. Each of the diseases we focus on represents a unique opportunity to make a meaningful difference for patients and their loved ones.

Alzheimer’s Disease

Alzheimer’s Disease (AD) is a progressive and irreversible brain disorder that slowly erodes memory, cognitive abilities, and essential functions for independent living. It is the most common form of dementia and poses significant emotional, physical, and financial challenges for individuals and their families.

Parkinson’s Disease

Parkinson’s Disease (PD) is a progressive neurological disorder that affects movement, balance, and coordination. It is primarily caused by the degeneration of dopamine-producing neurons in the brain, leading to motor symptoms such as tremors, stiffness, and slowed movement.

Rett Syndrome

Rett Syndrome (RS) is a rare neurological disorder that primarily affects girls, causing severe cognitive, motor, and communication impairments. It is typically diagnosed in early childhood and is often marked by a loss of previously acquired skills.

Pain

Pain is a complex and multifaceted experience that serves as the body’s warning system for injury or illness. While acute pain often resolves with treatment, chronic pain can persist for months or years, significantly impacting an individual’s quality of life.

Infantile Spasms

Infantile spasms are a rare and severe form of epilepsy that typically begin in infancy. These spasms are characterized by sudden, jerking movements and are often accompanied by developmental delays and abnormal brain wave patterns, requiring immediate medical attention.

Frontotemporal Dementia

Frontotemporal Dementia (FTD) is a group of neurodegenerative disorders that primarily affect the frontal and temporal lobes of the brain, leading to changes in behavior, personality, language, and movement. It is a major cause of dementia in individuals under the age of 65.

Fragile X Syndrome

Fragile X Syndrome (FXS) is the most common inherited cause of intellectual disability and developmental delays. It is a genetic condition that affects learning, behavior, and social interactions, often presenting alongside physical and emotional challenges.

Depression

Depression is a common yet serious mental health condition that affects how a person feels, thinks, and handles daily activities. It goes beyond temporary sadness, often disrupting an individual’s ability to function and diminishing their overall quality of life.

Angelman Syndrome

Angelman Syndrome is a rare genetic disorder that affects the nervous system, leading to developmental delays, movement and balance issues, minimal to no speech, and frequent seizures. Despite these challenges, individuals with Angelman Syndrome often exhibit a happy demeanor, with frequent smiling and laughter.

Stroke

A stroke is a medical emergency that occurs when blood flow to the brain is interrupted, either due to a blocked artery (ischemic stroke) or a ruptured blood vessel (hemorrhagic stroke). This disruption leads to brain cell death, resulting in physical, cognitive, and emotional impairments.

Helpful Resources

For HCPs considering blarcamesine in treatment protocols for patients exhibiting early AD dementia, or those seeking detailed drug information, the following resources are recommended:

Alzheimer’s Research and Support Organizations

Utilize resources from organizations like the Alzheimer’s Association at www.alz.org, which provide updates on treatment advances, professional caregiver support, and educational materials.

Clinical Trial Information

Review detailed trial data and protocol information for the recently completed blarcamesine open-label extension Phase IIb/III study available at ClinicalTrials.gov.